Results 241 to 250 of about 214,836 (336)

Contemporary and Emerging Therapies in the Management of Refractory Angina: A Clinical Review

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Refractory angina (RA) represents a growing challenge in clinical cardiology, particularly in patients with obstructive coronary artery disease (CAD) who remain symptomatic despite optimal medical therapy and who are not candidates for revascularization.
Alex Angers‐Goulet   +4 more
wiley   +1 more source

Incidence and Predictors of Hypoattenuated Thickening and Device‐Related Thrombus at Three Months Postprocedural CT Assessment Following Left Atrial Appendage Occlusion With Amplatzer Devices—A Single‐Center Cohort

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Left atrial appendage occlusion (LAAO) has become a valuable alternative to long‐term anticoagulation for stroke prevention in patients with non‐valvular atrial fibrillation (AF), especially in those at high bleeding risk. Hypoattenuated thickening (HAT) and device‐related thrombus (DRT) remain notable postprocedural concerns ...
Pierre Guilleminot   +7 more
wiley   +1 more source

Living at the Extremes [PDF]

open access: yes, 2010
Gerth, Nadine
core  

Nationwide Analysis of PCI After TAVR From the Netherlands Heart Registration

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Percutaneous coronary intervention (PCI) after transcatheter aortic valve replacement (TAVR) has gained interest as concomitant coronary artery disease (CAD) is now often treated conservatively before TAVR, and TAVR is increasingly used in younger patients with longer life expectancies. Therefore, more contemporary data on PCI after
Hugo M. Aarts   +7 more
wiley   +1 more source

Concentration–QTc Modeling to Support Clinical Development of Fezolinetant

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Fezolinetant is a non‐hormonal, selective neurokinin‐3 receptor antagonist that blocks neurokinin B activation of kisspeptin/neurokinin B/dynorphin neurons to thereby modulate neuronal activity in the thermoregulatory center. Fezolinetant has been approved in many regions, including North America, Europe, Asia, and Australia for the treatment ...
Jace C. Nielsen   +6 more
wiley   +1 more source

Drug‐Induced QT Prolongation: Associations Between Risk Classifications in a Swedish Clinical Decision Support System and Clinical Outcomes

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Potential adverse drug events can be signaled in Clinical Decision Support Systems (CDSSs). This study validated a Swedish CDSS (Janusmed Risk Profile) by investigating associations between calculated risk classifications of drugs with QT‐prolonging potential and registered related clinical outcomes.
Ola Nordqvist   +6 more
wiley   +1 more source

Cardiology for dummies [PDF]

open access: yes, 2011
van Loon, Gunther
core  

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy